Assetmark Inc. Purchases 719 Shares of Structure Therapeutics Inc. (NASDAQ:GPCR)

Assetmark Inc. boosted its position in shares of Structure Therapeutics Inc. (NASDAQ:GPCR) by 120.0% in the third quarter, HoldingsChannel reports. The fund owned 1,318 shares of the company’s stock after purchasing an additional 719 shares during the quarter. Assetmark Inc.’s holdings in Structure Therapeutics were worth $58,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also bought and sold shares of the company. Bank of Montreal Can acquired a new stake in shares of Structure Therapeutics in the 2nd quarter worth $1,064,000. Bellevue Group AG boosted its holdings in Structure Therapeutics by 2,858.7% in the first quarter. Bellevue Group AG now owns 363,926 shares of the company’s stock worth $15,598,000 after acquiring an additional 351,626 shares in the last quarter. Lighthouse Investment Partners LLC purchased a new stake in shares of Structure Therapeutics during the second quarter worth about $1,178,000. abrdn plc increased its holdings in shares of Structure Therapeutics by 132.7% during the third quarter. abrdn plc now owns 217,083 shares of the company’s stock valued at $9,528,000 after acquiring an additional 123,789 shares in the last quarter. Finally, First Light Asset Management LLC raised its position in shares of Structure Therapeutics by 296.1% in the 2nd quarter. First Light Asset Management LLC now owns 590,647 shares of the company’s stock valued at $23,195,000 after purchasing an additional 441,534 shares during the last quarter. 91.78% of the stock is owned by hedge funds and other institutional investors.

Structure Therapeutics Trading Down 7.1 %

GPCR opened at $31.75 on Tuesday. Structure Therapeutics Inc. has a 12-month low of $26.61 and a 12-month high of $66.38. The firm has a 50 day moving average of $39.38 and a two-hundred day moving average of $39.80. The firm has a market capitalization of $1.82 billion, a PE ratio of -42.77 and a beta of -3.23.

Wall Street Analyst Weigh In

Several analysts have weighed in on the stock. JMP Securities dropped their target price on shares of Structure Therapeutics from $91.00 to $86.00 and set a “market outperform” rating on the stock in a research report on Friday, August 9th. Cantor Fitzgerald reissued an “overweight” rating and set a $65.00 price objective on shares of Structure Therapeutics in a report on Monday, September 23rd. Finally, Morgan Stanley began coverage on Structure Therapeutics in a research report on Monday, September 23rd. They issued an “overweight” rating and a $118.00 target price on the stock. Six equities research analysts have rated the stock with a buy rating, According to MarketBeat.com, Structure Therapeutics presently has a consensus rating of “Buy” and a consensus price target of $86.80.

Structure Therapeutics Company Profile

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company’s lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.